Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Danaher (DHR) delivered earnings and revenue surprises of 4.15% and 1.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Danaher (DHR) Tops Q1 Earnings and Revenue Estimates

WASHINGTON , April 21, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2022. For the quarter ended April 1, 2022, net earnings were $1.7 billion, or $2.31 per diluted common share which represents a 1.0% increase over the comparable 2021 period.

Danaher Reports First Quarter 2022 Results

UnitedHealth Group

Wells Fargo

Today's Research Daily features Q1 earnings season scorecard and fresh reports on UnitedHealth(UNH), Danaher (DHR), Wells Fargo (WFC) & others.

Q1 Scorecard and Analyst Reports for UnitedHealth, Danaher & Wells Fargo

WASHINGTON , April 12, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its 4.75% Series A Mandatory Convertible Preferred Stock (the "Preferred Stock"), will automatically convert into shares of the Company's Common Stock on April 15, 2022 (the "Conversion Date"). The conversion rate for each share of Preferred Stock will be 6.6632 shares of the Company's Common Stock.

Danaher Announces Conversion Date For Series A Mandatory Convertible Preferred Stock

Danaher Corporation (NYSE:DHR) has been a stock to watch since the pandemic broke out. The company which manufactures diagnostic consumables recorded growth in revenue during the pandemic.

Danaher Corporation's price rally nears a stop. Should you sell now?

Sumitomo Corp

SSUMY vs. DHR: Which Stock Is the Better Value Option?

CORALVILLE, Iowa--(BUSINESS WIRE)-- #AlignProgram--Catalytic Data Science joins IDT's Align program, bolstering its roster of sequencing providers working collectively to advance genomics research.

Catalytic Data Science Joins Integrated DNA Technologies Align Program

American Express

Dollar General

Home Depot

Occidental Petroleum

Prologis

Steel Dynamics

In 2021, dividend stocks increased their payouts by 17%. In 2022, they're expected to average 3%.

7 Dividend Stocks to Buy Now for Boosting Payout

WASHINGTON, March 21, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2022 on Thursday, April 21, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

Danaher Schedules First Quarter 2022 Earnings Conference Call

Anthem

Centene

Quest Diagnostics

PerkinElmer

West Pharmaceutical Services

When the markets go through the massive transitions they're seeing right now, it's a great time to add quality healthcare stocks. The post 7 Healthcare Stocks to Buy for the Long Term appeared first on InvestorPlace.

7 Healthcare Stocks to Buy for the Long Term

CORALVILLE, Iowa--(BUSINESS WIRE)-- #AlignProgram--Integrated DNA Technologies adds MLL Munich Leukemia Laboratory to its Align Program. The expanding initiative focuses on advancing genomics research.

Integrated DNA Technologies Adds MLL Munich Leukemia Laboratory to Align Program

Boeing

Apple

Salesforce

NVIDIA

Boeing, Apple and Salesforce and Wells Fargo among the Club holdings that are moving Friday.

Investing Club: What we're watching Friday afternoon — tech rising, Danaher's big week, Boeing bump

Danaher Corp (DHR) Presents at Cowen Health Care Broker Conference (Transcript)

Danaher yet again delivered strong quarterly results. Revenue grew 20.5% in 4Q and 32.0% for the full year.

Danaher: Best Healthcare Company In Inflationary Environment

I prefer a healthy mix between high-yield and low-yield dividend growth investments in my long-term portfolio.

Danaher: So Much Cash And Potential Capital Gains

Crane Company

Carlisle Companies

Griffon

Healthy demand and improving manufacturing activities benefit players in the Zacks Diversified Operations industry. DHR, CSL, CR and GFF are stocks with strong prospects.

4 Stocks to Gain From the Promising Diversified Operations Industry

BRRAY vs. DHR: Which Stock Is the Better Value Option?

BRRAY vs. DHR: Which Stock Should Value Investors Buy Now?

WASHINGTON, March 1, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Cowen Healthcare Conference on Tuesday, March 8, 2022 at 9:10 a.m.

DANAHER TO PRESENT AT COWEN HEALTHCARE CONFERENCE

Allstate

Diamondback Energy

Foot Locker

L3Harris

After years of a low interest rate environment, many investors have turned to equities, not only for the growth potential but also for solid and dependable dividends that help to provide an income stream.

5 ‘Strong Buy' Stocks With Dividend Hikes Expected This Week

The life sciences and diagnostics company will do well if the pandemic gets worse.

This Under-the-Radar Industrial Stock Can Buy You Some Portfolio Protection

Alphabet

Analog Devices

Ares Management

J.B. Hunt Transport Services

Nasdaq futures traded sharply lower this morning after Meta Platforms, Inc. (NASDAQ: FB) reported worse-than-expected Q4 EPS results and issued weak forecast. When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced.

Alphabet And 4 Other Stocks Sold By Insiders

All in, this was a solid quarter from Danaher and exemplary of the type of company we believe investors must focus on in this volatile market.

Cramer's Investing Club: Danaher once again delivers reliable earnings, and that's why we own the stock

Danaher's (DHR) Q4 earnings reflect gains from solid segmental results and higher gross and operating margins. High costs and expenses restrict margin growth.

Danaher (DHR) Tops on Q4 Earnings, Suffers From Cost Woes

Danaher Corporation (DHR) CEO Rainer Blair on Q4 2021 Results - Earnings Call Transcript

Danaher Corporation (NYSE: DHR) logged Q4 FY21 adjusted EPS of $2.69 up 29% Y/Y, surpassing the estimate of $2.51. Sales increased 20.5% to $8.1 billion, with 19.5% non-GAAP core revenue growth, beating the $7.92 billion estimate.

News for Danaher Stock (DHR)